[1]付晓英,李 光,靳延利.骨髓中CDKN1C的表达在骨髓增生异常综合征和继发性急性髓系白血病患者中检测的临床意义[J].现代检验医学杂志,2017,32(05):36-40.[doi:10.3969/j.issn.1671-7414.2017.05.010]
　FU Xiao-ying,LI Guang,JIN Yan-li.Clinical Significance of Expression of CDKN1C in Bone Marrow in Patients with Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia[J].Journal of Modern Laboratory Medicine,2017,32(05):36-40.[doi:10.3969/j.issn.1671-7414.2017.05.010]
点击复制

骨髓中CDKN1C的表达在骨髓增生异常综合征和继发性急性髓系白血病患者中检测的临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
36-40
栏目:
论著
出版日期:
2017-11-02

文章信息/Info

Title:
Clinical Significance of Expression of CDKN1C in Bone Marrow in Patients with Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia
文章编号:
1671-7414(2017)05-036-05
作者:
付晓英1; 李 光2; 靳延利3
1.宝鸡市中心医院血液科,陕西宝鸡 721008; 2.西安市中心医院 西安市血液病研究所,西安 710003; 3.延安市人民医院骨科一病区,陕西延安 716000
Author(s):
FU Xiao-ying1; LI Guang2; JIN Yan-li3
1.Department of Hematology,Baoji Central Hospital,Shaanxi Baoji 721008,China; 2.Xi'an Central Hospital,Xi'an Institute of Hematology,Xi'an 710003,China; 3.Department of Qrthopedics Ward.Yan'an People's Hospital,Shaanxi Yan'an 716000 China
关键词:
蛋白细胞周期激酶抑制剂1C(CDKN1C);  骨髓增生异常综合征;  继发性急性髓系白血病;  骨髓
分类号:
R551; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.05.010
文献标志码:
A
摘要:
目的 探讨骨髓中蛋白细胞周期激酶抑制剂1C(CDKN1C)的表达在骨髓增生异常综合征(MDS)和继发性急性髓系白血病(AML)患者中检测的临床意义。方法 选取125例MDS/AML患者作为研究对象,同时选取20例健康人群作为健康对照组,分析MDS/AML患者骨髓CD34+ 细胞中CDKN1C mRNA和蛋白表达水平,比较不同CDKN1C的表达水平MDS患者生存率,采用Cox回归分析MDS和AML患者生存率影响因素,并分析治疗方法对不同CDKN1C的表达水平MDS患者生存率的影响。结果 MDS/AML患者骨髓CD34+细胞中CDKN1C mRNA和蛋白表达水平显著高于健康对照组(t=5.324,7.326,P=0.002,0.000),且与BM计数呈正相关(r=2.014,P=0.004); CDKN1C高表达水平组患者的生存率显著低于CDKN1C低表达水平组和CDKN1C中表达水平组(P<0.05); Cox回归分析结果显示高龄、高BM计数、细胞遗传学风险差以及CDKN1C阳性显著影响MDS/AML患者生存率(95%CI=1.10～1.32,1.92～4.40,1.18～2.67,1.03～2.32,P=0.034～0.000); MDS/AML化疗的CDKN1C阳性表达组患者生存率显著低于CDKN1C阴性表达组患者(t=5.314,P=0.002)。结论 MDS/AML患者骨髓中CDKN1C的表达显著增高,CDKN1C高表达显著影响化疗MDS/AML患者的生存率。
Abstract:
Abstract:Objective To investigate the expression of CDKN1C in bone marrow in myelodysplastic syndromes and clinical significance of thedetection of syndrome and secondary acute myeloid leukemia patients.Methods 125 patients with MDS/AML were selected as the research object,and selected 20 cases of healthy people as healthy control group,and to investigate the mRNA and protein expression in CD34+ cells in bone marrow the expression of MDS/AML in patients and the survival rate of different expression of CDKN1C,to analyze the factors for survival rate of patients with MDS by Cox regression,and analyze the different treatment methods in patients with MDS/AML.Results The expression levels of CDKN1C mRNA and protein ofbone marrow CD34+ cells in the patients with MDS/AML were significantly higher than the healthy control group(t=5.324,7.326; P=0.002,0.000),and which was positive with BM count(r=2.014,P=0.004); the survival rate of CDKN1C high expression levels in patients with MDS/AML was significantly lower than that of the low expression of CDKN1C group and intermediate CDKN1C expression group(P<0.05).Cox regression analysis showed that age,high BM count,cytogenetic risk difference and CDKN1C positive significantly affectthe survival rate of patients with MDS/AML(95%CI=1.10～1.32,1.92～4.40,1.18～2.67,1.03～2.32,P=0.034～0.000).MDS/AML chemotherapy in CDKN1C positive group was significantly lower than the survival rate of patients with CDKN1C negative expression group(t=5.314,P=0.002).Conclusion The expression of CDKN1C in bone marrow of patients with MDS/AML was significantly increased,and the high expression of CDKN1CMDS/AML effect of chemotherapy on the survival rate of patients with MDS/AML.

参考文献/References:

[1] 冯秀梅,许洪志,张婧瑶,等.再生障碍性贫血、骨髓增生异常综合征和急性髓系白血病患者CD4+T细胞亚群转录因子表达的变化及其临床意义[J].中国实验血液学杂志,2014,22(4):1038-1042. Feng XM,Xu HZ,Zhang JY,et al.Expressive changes of CD4 + T cellsubsets transcription factors in patients with aplastic anemia,myelodysplasticsyndrome and acute myeloid leukemia and their clinical significances[J].Journal of Experimental Hematology,2014,22(4):1038-1042.
[2] Garcia-Manero G.Myelodysplastic syndromes:2014 u-pdate on diagnosis,risk-stratification,and management[J].American Journal of Hematology,2011,86(1):97-108.
[3] Greenberg PL,Tuechler H,Schanz J,et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood,2012,120(12):2454-2465.
[4] 华海应,高华强,朱文艳,等.Wilms肿瘤基因在骨髓增生异常综合征与急性白血病患者骨髓细胞中的表达及其临床意义[J].江苏医药,2015,41(20):2394-2396. Hua HY,Gao HQ,Zhu WY,et al.Expression and clinical significanceof WT1 in bone marrow cells in patients with myelodysplastic syndrome and acuteleukemia[J].Jiangsu Medicine Journal,2015,41(20):2394-2396.
[5] Ferrara F.Conventional chemotherapy or hypomethylating agents for olderpatients with acute myeloid leukaemia?[J].Hematological Oncology,2014,32(1):1-9.
[6] Bertoli S,Bories P,Béné MC,et al.Prognostic impact of day 15 blastclearance in risk-adapted remission induction chemotherapy for younger patientswith acute myeloid leukemia:long-term results of the multicenter prospectiveLAM-2001 trial by the GOELAMS study group[J].Haematologica,2014,99(1):46-53.
[7] Craddock C,Quek L,Goardon N,et al.Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia[J].Leukemia:Official Journal of the Leukemia Society of America Leukemia Research Fund U K,2013,27(5):1028-1036.
[8] Schiller GJ.High-risk acute myelogenous leukemia:treatment today… andtomorrow[J].Hematology,2013,2013(1):201-208.
[9] Will B,Zhou L,Vogler TO,et al.Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations[J].Blood,2012,120(10):2076-2086.
[10] Brenet F,Kermani P,Spektor R,et al.TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy[J].Journal of Experimental Medicine,2013,210(3):623-639.
[11] Pellagatti A,Benner A,Mills KI,et al.Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes[J].Journal of Clinical Oncology,2013,31(28):3557-3564.
[12] 卢 丹,秦亚溱,李玲娣,等.骨髓增生异常综合征患者骨髓及外周血中WT1及PRAME基因的表达研究[J].中国实验血液学杂志,2014,22(2):370-376. Lu D,Qin YZ,Li LD,et al.Expression of WT1 and PRAME genes in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome[J].Journal of Experimental Hematology,2014,22(2):370-376.
[13] Starmans MH,Lieuwes NG,Span PN,et al.Independent and functional validation of a multi-tumour-type proliferation signature[J].British Journal ofCancer,2012,107(3):508-515.
[14] 黄 莹,文 静,李虹颖,等.miR-550a-5p在骨髓增生异常综合征中的表达及其靶基因预测[J].中国实验血液学杂志,2016,24(5):1476-1483. Huang Y,Wen J,Li HY,et al.Expression of miR-550a-5p in myelodysplastic syndromes and its prediction of target gene[J].Journal of Experimental Hematology,2016,24(5):1476-1483.
[15] Zhou L,McMahon C,Bhagat T,et al.Reduced SM-AD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase[J].Cancer Res,2011,71(3):955-963.
[16] 吕远飞,闫振宇,陈乃耀,等.淋巴细胞亚群在再生障碍性贫血和低增生性骨髓增生异常综合征患者外周血中的表达分析[J].中国实验血液学杂志,2016,24(5):1505-1510. L(¨overu)YF,Yan ZY,Chen NY,et al.Analysis of lymphocyte subsets inperipheral blood of patients with aplastic anemia or hypoplastic myelodysplastic syndrome[J].Journal of Experimental Hematology,2016,24(5):1505-1510.

相似文献/References:

[1]王伟伟,张 夏,黄传荣,等.血清LDH,TBIL,IBIL和Hcy水平检测 在MA和MDS临床鉴别诊断中的作用研究[J].现代检验医学杂志,2015,30(01):111.[doi:10.3969/j.issn.1671-7414.2015.01.031]
　WANG Wei-wei,ZHANG Xia,HUANG Chuan-rong,et al.Research on Detecting Serum LDH,TBIL,IBIL and Hcy Levels in Clinical Differential Diagnosis of MA and MDS[J].Journal of Modern Laboratory Medicine,2015,30(05):111.[doi:10.3969/j.issn.1671-7414.2015.01.031]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基金项目(2013JM4016)。 作者简介:付晓英(1979-),女,本科,主管检验师,研究方向:骨髓检验,E-mail:fuxiaoying1979@163.com。 通讯作者:靳延利,E-mail:1409330421@qq.com。
更新日期/Last Update: 1900-01-01